Treatment of Osteoporosis - TOP1 Clinical Study
TOP1
Treatment of Osteoporosis by Panaceo: Randomized, Double-blind, Controlled, Study Assessed Effect on Bone Mineral Density and Bone Turnover of Panaceo Compared to Placebo in Osteoporotic Patients
1 other identifier
interventional
100
0 countries
N/A
Brief Summary
This study investigates the effect of zeolite on bone mineral metabolism. The clinical parameters include bone mineral density, bone remodelling markers, fractures and fallings, the subjective evaluation of the overall health status and intensity of the musculoskeletal pain measured by VAS.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jan 2015
Typical duration for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 14, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 20, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
March 20, 2017
CompletedFirst Submitted
Initial submission to the registry
March 8, 2019
CompletedFirst Posted
Study publicly available on registry
April 3, 2019
CompletedApril 3, 2019
April 1, 2019
2.2 years
March 8, 2019
April 2, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
Change of BMD (Bone mineral density)
BMD measurements are used to see how well osteoporosis treatments are working
0-6-12 months
Secondary Outcomes (2)
Cange of Bone remodelling marker Osteocalcin
0-6-12 months
Cange of Bone remodelling marker Betacross laps
0-6-12 months
Other Outcomes (3)
Fractures and fallings
12 months
Intensity of the musculoskeletal pain measured by VAS
0-12 months
Subjective evaluation of the overall health status and 6.
0-12 months
Study Arms (2)
zeolite
ACTIVE COMPARATOR50 subjects receive the substance 3 times per day as powder
cellulose
PLACEBO COMPARATOR50 subjects receive the substance 3 times per day as powder
Interventions
Eligibility Criteria
You may qualify if:
- subjects with osteoporosis Among those, as a subgroup, 20 subjects with diabetes type 2 and osteoporosis
- The osteoporosis- was diagnosed by standard DXA measurement (BMD T-score: - 2.5 or below )
You may not qualify if:
- chronic renal failure, secondary osteoporosis
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Polyclinic K-centerlead
- University of Rijekacollaborator
Related Publications (2)
Kraljevic Pavelic S, Saftic Martinovic L, Simovic Medica J, Zuvic M, Perdija Z, Krpan D, Eisenwagen S, Orct T, Pavelic K. Clinical Evaluation of a Defined Zeolite-Clinoptilolite Supplementation Effect on the Selected Blood Parameters of Patients. Front Med (Lausanne). 2022 May 27;9:851782. doi: 10.3389/fmed.2022.851782. eCollection 2022.
PMID: 35712111DERIVEDKraljevic Pavelic S, Micek V, Bobinac D, Bazdulj E, Gianoncelli A, Krpan D, Zuvic M, Eisenwagen S, Stambrook PJ, Pavelic K. Treatment of osteoporosis with a modified zeolite shows beneficial effects in an osteoporotic rat model and a human clinical trial. Exp Biol Med (Maywood). 2021 Mar;246(5):529-537. doi: 10.1177/1535370220968752. Epub 2020 Nov 12.
PMID: 33183068DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Prof.dr.sc. Dalibor Krpan, prim.dr.med.
Study Record Dates
First Submitted
March 8, 2019
First Posted
April 3, 2019
Study Start
January 14, 2015
Primary Completion
March 20, 2017
Study Completion
March 20, 2017
Last Updated
April 3, 2019
Record last verified: 2019-04